<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-KTS8RJS4</identifier><date>2016</date><creator>Avsec, Damjan</creator><creator>Flegar, Ines</creator><relation>documents/doc/K/URN_NBN_SI_doc-KTS8RJS4_001.pdf</relation><relation>documents/doc/K/URN_NBN_SI_doc-KTS8RJS4_001.txt</relation><format format_type="issue">6</format><format format_type="volume">67</format><format format_type="type">article</format><format format_type="extent">str. 374-379</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">30044711</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-KTS8RJS4</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">gensko zdravljenje</subject><subject language_type_id="slv">Huntingtonova horea</subject><subject language_type_id="slv">proteini z domeno cinkovega prsta</subject><subject language_type_id="slv">protismiselni oligonukleotid</subject><subject language_type_id="slv">RNA-interferenca</subject><title>Gene therapy for Huntington's disease</title><title>Gensko zdravljenje Huntingtonove bolezni</title></Record>